Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile

Bolt Biotherapeutics Company

BOLT
US0977021049
A2QNZN

Price

0.68
Today +/-
+0.03
Today %
+4.35 %
P

Bolt Biotherapeutics stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Bolt Biotherapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Bolt Biotherapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Bolt Biotherapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Bolt Biotherapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Bolt Biotherapeutics Stock Price History

DateBolt Biotherapeutics Price
10/25/20240.68 undefined
10/24/20240.65 undefined
10/23/20240.65 undefined
10/22/20240.66 undefined
10/21/20240.64 undefined
10/18/20240.63 undefined
10/17/20240.64 undefined
10/16/20240.64 undefined
10/15/20240.63 undefined
10/14/20240.63 undefined
10/11/20240.64 undefined
10/10/20240.64 undefined
10/9/20240.64 undefined
10/8/20240.64 undefined
10/7/20240.67 undefined
10/4/20240.65 undefined
10/3/20240.64 undefined
10/2/20240.65 undefined
10/1/20240.65 undefined
9/30/20240.65 undefined

Bolt Biotherapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Bolt Biotherapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Bolt Biotherapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Bolt Biotherapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Bolt Biotherapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Bolt Biotherapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Bolt Biotherapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Bolt Biotherapeutics’s growth potential.

Bolt Biotherapeutics Revenue, EBIT and net profit per share

DateBolt Biotherapeutics RevenueBolt Biotherapeutics EBITBolt Biotherapeutics Net Income
2029e51 M undefined0 undefined-15.61 M undefined
2028e25.5 M undefined-48.04 M undefined-15.22 M undefined
2027e11.9 M undefined-59.6 M undefined-21.46 M undefined
2026e5.75 M undefined-56.08 M undefined-43.12 M undefined
2025e3.72 M undefined-57.65 M undefined-49.95 M undefined
2024e9.16 M undefined-69.15 M undefined-59.12 M undefined
20237.88 M undefined-76.2 M undefined-69.2 M undefined
20225.73 M undefined-90.32 M undefined-88.1 M undefined
20211.26 M undefined-92.79 M undefined-98.59 M undefined
2020230,000 undefined-49.18 M undefined-60.73 M undefined
2019220,000 undefined-30.97 M undefined-30.49 M undefined
20180 undefined-11.63 M undefined-11.59 M undefined

Bolt Biotherapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2018201920202021202220232024e2025e2026e2027e2028e2029e
000157935112551
----400.0040.0028.57-66.6766.67120.00127.27104.00
------------
000000000000
-11-30-49-92-90-76-69-57-56-59-480
----9,200.00-1,800.00-1,085.71-766.67-1,900.00-1,120.00-536.36-192.00-
-11-30-60-98-88-69-59-49-43-21-15-15
-172.73100.0063.33-10.20-21.59-14.49-16.95-12.24-51.16-28.57-
34.5234.5236.3337.437.3637.81000000
------------
Details

Keystats

Revenue and Growth

The Bolt Biotherapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Bolt Biotherapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201820192020202120222023
           
13.634.822.8186.2168.9102.19
000000
000000
000000
0.51.12.52.93.93.52
14.135.925.3189.1172.8105.71
1.411.516.430.628.524.08
00085.323.926.41
000000
000000
000000
0.414.82.62.63.59
1.812.521.2118.55554.08
15.948.446.5307.6227.8159.78
           
28.477.5105.3000
1.21.83.5457.4467.5476.99
-17.2-47.7-108.4-207-295.1-364.29
000-300-90037
000000
12.431.60.4250.1171.5112.74
0.92.11.63.63.62.99
1.868.214.917.515.27
00.61.52.922.2
000000
000000
2.78.711.321.423.120.46
000000
000000
0.88.134.936.333.226.59
0.88.134.936.333.226.59
3.516.846.257.756.347.04
15.948.446.6307.8227.8159.78
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Bolt Biotherapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Bolt Biotherapeutics's financial health and stability.

Assets

Bolt Biotherapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Bolt Biotherapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Bolt Biotherapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Bolt Biotherapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201820192020202120222023
-11-30-60-98-88-69
0001,0001,0001,000
000000
12-220-3-9
011519127
000000
000000
-9-26-47-57-76-69
00-3-2-10
00-20-2325771
00-17-2295971
000000
000000
00031100
19483931100
194839000
000000
821-2821-181
-10.16-26.85-50.57-59.41-78.45-69.73
000000

Bolt Biotherapeutics stock margins

The Bolt Biotherapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bolt Biotherapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bolt Biotherapeutics.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Bolt Biotherapeutics's sales revenue. A higher gross margin percentage indicates that the Bolt Biotherapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Bolt Biotherapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Bolt Biotherapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Bolt Biotherapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Bolt Biotherapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Bolt Biotherapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Bolt Biotherapeutics Margin History

Bolt Biotherapeutics Gross marginBolt Biotherapeutics Profit marginBolt Biotherapeutics EBIT marginBolt Biotherapeutics Profit margin
2029e0 %0 %-30.61 %
2028e0 %-188.39 %-59.69 %
2027e0 %-500.85 %-180.37 %
2026e0 %-975.86 %-750.35 %
2025e0 %-1,551.72 %-1,344.61 %
2024e0 %-754.89 %-645.45 %
20230 %-967.45 %-878.58 %
20220 %-1,576.27 %-1,537.52 %
20210 %-7,364.29 %-7,824.6 %
20200 %-21,382.61 %-26,404.35 %
20190 %-14,077.27 %-13,859.09 %
20180 %0 %0 %

Bolt Biotherapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Bolt Biotherapeutics earnings per share therefore indicates how much revenue Bolt Biotherapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Bolt Biotherapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Bolt Biotherapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Bolt Biotherapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Bolt Biotherapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Bolt Biotherapeutics Revenue, EBIT and net profit per share

DateBolt Biotherapeutics Sales per ShareBolt Biotherapeutics EBIT per shareBolt Biotherapeutics Earnings per Share
2029e1.33 undefined0 undefined-0.41 undefined
2028e0.67 undefined0 undefined-0.4 undefined
2027e0.31 undefined0 undefined-0.56 undefined
2026e0.15 undefined0 undefined-1.13 undefined
2025e0.1 undefined0 undefined-1.31 undefined
2024e0.24 undefined0 undefined-1.55 undefined
20230.21 undefined-2.02 undefined-1.83 undefined
20220.15 undefined-2.42 undefined-2.36 undefined
20210.03 undefined-2.48 undefined-2.64 undefined
20200.01 undefined-1.35 undefined-1.67 undefined
20190.01 undefined-0.9 undefined-0.88 undefined
20180 undefined-0.34 undefined-0.34 undefined

Bolt Biotherapeutics business model

Bolt Biotherapeutics is one of the most popular companies on Eulerpool.com.

Bolt Biotherapeutics Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Bolt Biotherapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Bolt Biotherapeutics shares outstanding

The number of shares was Bolt Biotherapeutics in 2023 — This indicates how many shares 37.812 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Bolt Biotherapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Bolt Biotherapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Bolt Biotherapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Bolt Biotherapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Bolt Biotherapeutics.

Bolt Biotherapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.49 -0.46  (6.05 %)2024 Q2
3/31/2024-0.52 -0.28  (46.17 %)2024 Q1
12/31/2023-0.49 -0.47  (4.34 %)2023 Q4
9/30/2023-0.51 -0.43  (15.69 %)2023 Q3
6/30/2023-0.5 -0.48  (3.3 %)2023 Q2
3/31/2023-0.52 -0.45  (13.78 %)2023 Q1
12/31/2022-0.61 -0.53  (13.16 %)2022 Q4
9/30/2022-0.57 -0.58  (-0.94 %)2022 Q3
6/30/2022-0.69 -0.61  (11.73 %)2022 Q2
3/31/2022-0.73 -0.64  (12.56 %)2022 Q1
1
2

Bolt Biotherapeutics shareholders

%
Name
Stocks
Change
Date
9.54585 % Tang Capital Management, LLC3,652,24495,20412/31/2023
9.20358 % Vivo Capital, LLC3,521,291-346,60012/31/2023
7.19926 % Sofinnova Investments, Inc2,754,437012/31/2023
6.42697 % Citadel Advisors LLC2,458,958-394,67612/31/2023
4.06047 % Newtyn Management, LLC1,553,535533,53512/31/2023
4.02771 % OrbiMed Advisors, LLC1,541,000012/31/2023
3.18944 % Engleman Edgar G1,220,28113/1/2023
3.05006 % Nan Fung Life Sciences1,166,952012/31/2023
2.74217 % Samsara BioCapital, LLC1,049,153012/31/2023
2.43369 % The Vanguard Group, Inc.931,1296,86412/31/2023
1
2
3
4
5
...
10

Bolt Biotherapeutics Executives and Management Board

Dr. Randall Schatzman68
Bolt Biotherapeutics Chief Executive Officer, Director (since 2019)
Compensation 2.24 M
Dr. Edith Perez66
Bolt Biotherapeutics Chief Medical Officer
Compensation 1.14 M
Mr. William Quinn52
Bolt Biotherapeutics Chief Financial Officer
Compensation 1.06 M
Mr. Grant Yonehiro59
Bolt Biotherapeutics Chief Business Officer
Compensation 968,768
Mr. Brian O'Callaghan54
Bolt Biotherapeutics Independent Director
Compensation 168,651
1
2
3

Bolt Biotherapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
SupplierCustomer0,490,66-0,650,470,73-
SupplierCustomer0,38-0,010,410,590,70-
1

Most common questions regarding Bolt Biotherapeutics

What is the P/E ratio of Bolt Biotherapeutics 2024?

The Bolt Biotherapeutics P/E ratio is -0.43.

What is the P/S ratio of Bolt Biotherapeutics 2024?

The Bolt Biotherapeutics P/S ratio is 2.8.

What is the Quality Investing of Bolt Biotherapeutics?

The Quality Investing for Bolt Biotherapeutics is 4/10.

What is the revenue of Bolt Biotherapeutics 2024?

The expected Bolt Biotherapeutics revenue is 9.16 M USD.

How high is the profit of Bolt Biotherapeutics 2024?

The expected Bolt Biotherapeutics profit is -59.12 M USD.

What is the business model of Bolt Biotherapeutics

No history available for Bolt Biotherapeutics.

What is the Bolt Biotherapeutics dividend?

Bolt Biotherapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Bolt Biotherapeutics pay dividends?

The dividend cannot currently be calculated for Bolt Biotherapeutics or the company does not pay out a dividend.

What is the Bolt Biotherapeutics ISIN?

The ISIN of Bolt Biotherapeutics is US0977021049.

What is the Bolt Biotherapeutics WKN?

The WKN of Bolt Biotherapeutics is A2QNZN.

What is the Bolt Biotherapeutics ticker?

The ticker of Bolt Biotherapeutics is BOLT.

How much dividend does Bolt Biotherapeutics pay?

Over the past 12 months, Bolt Biotherapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bolt Biotherapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Bolt Biotherapeutics?

The current dividend yield of Bolt Biotherapeutics is .

When does Bolt Biotherapeutics pay dividends?

Bolt Biotherapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Bolt Biotherapeutics?

Bolt Biotherapeutics paid dividends every year for the past 0 years.

What is the dividend of Bolt Biotherapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Bolt Biotherapeutics located?

Bolt Biotherapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bolt Biotherapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bolt Biotherapeutics from 10/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/28/2024.

When did Bolt Biotherapeutics pay the last dividend?

The last dividend was paid out on 10/28/2024.

What was the dividend of Bolt Biotherapeutics in the year 2023?

In the year 2023, Bolt Biotherapeutics distributed 0 USD as dividends.

In which currency does Bolt Biotherapeutics pay out the dividend?

The dividends of Bolt Biotherapeutics are distributed in USD.

All fundamentals about Bolt Biotherapeutics

Our stock analysis for Bolt Biotherapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bolt Biotherapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.